Nanobac announces Baylor initial results for nanoparticle and gall stone formation study

Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).

This potentially represents a previously unrecognized factor in the development of cholecystitis and cholelithiasis disease.

The project seeks to determine if human cell derived nanoparticles are pathogenic and induce inflammatory (cholecystitis) and calcific pathologic (cholelithiasis) disease. The project also seeks to confirm prior Nanobac studies, conducted in China, that Nanobac’s diagnostic test specifically identifies CNPs.

The study results suggest a strong association between CNPs and cholelithiasis and conclude that it is conceivable that a specific therapy for CNPs may prevent cholecystitis and reduce the need for surgical intervention. The results were given at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. The abstract was published in “Hepatology 46(4) 699A 1036 Suppl S, 2007” issue.

Dr. Maniscalco, co-chair of Nanobac, stated, “We believe that CNPs play a major role in pathologic calcification and a multitude of associated disease states such as calcification of arteries and organs. This study, conducted by one of the lead medical and research facilities in the United States, lends credence to our beliefs.”